drugset
Drugs / haNK
last change Sep 2022 re-read 2 minutes ago

haNK

also known as haNK for infusion

Cell therapy

Developed for
malignant pancreatic neoplasm · colorectal cancer · cutaneous neuroendocrine carcinoma · non-small cell lung carcinoma · triple-negative breast carcinoma · chordoma · head and neck squamous cell carcinoma · hepatocellular carcinoma
+4 more · non-Hodgkin lymphoma · ovarian carcinoma · squamous cell carcinoma · urothelial carcinoma
Investigated by
ImmunityBio, Inc.

Trials 18 · a red edge is where a trial was stopped

today NCT03853317 · Ph 2 NCT03563157 · Ph 1/2 NCT03554109 · Ph 2 NCT03647423 · Ph 1/2 NCT03169777 · Ph 1/2 NCT03563144 · Ph 2 NCT03586869 · Ph 1/2 NCT03574649 · Ph 2 NCT03563170 · Ph 1/2 NCT03169738 · Ph 1/2 NCT03387111 · Ph 1/2 NCT03197584 · Ph 1/2 NCT03167164 · Ph 1/2 NCT03169790 · Ph 1/2 NCT03197571 · Ph 1/2 NCT03175666 · Ph 1/2 NCT03169764 · Ph 1/2 NCT03329248 · Ph 1/2
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/214 trials
Phase 1/2 NCT03563157 Sep 2018 → Apr 2019 colorectal cancer ImmunityBio, Inc. Terminated No outcome recorded
Phase 1/2 NCT03647423 Aug 2018 → Aug 2020 chordoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03169777 Aug 2018 → Jan 2019 colorectal cancer ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03586869 Jul 2018 → Apr 2019 malignant pancreatic neoplasm ImmunityBio, Inc. Terminated No outcome recorded
Phase 1/2 NCT03563170 May 2018 → Aug 2019 hepatocellular carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03169738 Feb 2018 → Jan 2019 non-small cell lung carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03387111 Jan 2018 → Apr 2019 squamous cell carcinoma ImmunityBio, Inc. Terminated No outcome recorded
Phase 1/2 NCT03197584 Dec 2017 → Feb 2019 ovarian carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03167164 Dec 2017 → Jan 2019 cutaneous neuroendocrine carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT03169790 Dec 2017 → Jan 2019 non-Hodgkin lymphoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 24 trials
Phase 2 NCT03853317 Feb 2020 → Sep 2021 cutaneous neuroendocrine carcinoma ImmunityBio, Inc. Terminated No outcome recorded
Phase 2 NCT03554109 Sep 2018 → Jun 2020 triple-negative breast carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 2 NCT03563144 Aug 2018 → Dec 2019 malignant pancreatic neoplasm ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 2 NCT03574649 Jun → Aug 2018 non-small cell lung carcinoma ImmunityBio, Inc. Withdrawn No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03167177 Background Dec 2017 → Jan 2019 melanoma ImmunityBio, Inc. Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as haNK ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574649 ↗
18

NCT03169764 ↗

NCT03197571 ↗

NCT03197584 ↗

NCT03563144 ↗

NCT03329248 ↗

NCT03647423 ↗

NCT03853317 ↗

NCT03387111 ↗

NCT03563157 ↗

NCT03586869 ↗

NCT03167177 ↗

NCT03169777 ↗

NCT03563170 ↗

NCT03169790 ↗

NCT03169738 ↗

NCT03167164 ↗

NCT03554109 ↗

NCT03175666 ↗
Known as haNK for infusion “NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)” NCT03574649 ↗
2

“Biological: haNK for infusion” NCT03387111 ↗

“Biological: haNK for infusion” NCT03586869 ↗
Modality Cell therapy “NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)” NCT03167164 ↗
Route Intravenous “Suspension for Intravenous [IV] Infusion” NCT03169738 ↗